- Home
- SDHC vs RXST Comparison
SDHC vs RXST Comparison
Compare SDHC & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- RXST
- Stock Information
- Founded
- SDHC 2008
- RXST 1997
- Country
- SDHC United States
- RXST United States
- Employees
- SDHC N/A
- RXST N/A
- Industry
- SDHC
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SDHC
- RXST Health Care
- Exchange
- SDHC Nasdaq
- RXST Nasdaq
- Market Cap
- SDHC 1.2B
- RXST 1.0B
- IPO Year
- SDHC 2024
- RXST 2021
- Fundamental
- Price
- SDHC $18.88
- RXST $14.43
- Analyst Decision
- SDHC Hold
- RXST Buy
- Analyst Count
- SDHC 4
- RXST 10
- Target Price
- SDHC $30.25
- RXST $38.50
- AVG Volume (30 Days)
- SDHC 65.6K
- RXST 1.2M
- Earning Date
- SDHC 05-13-2025
- RXST 05-07-2025
- Dividend Yield
- SDHC N/A
- RXST N/A
- EPS Growth
- SDHC N/A
- RXST N/A
- EPS
- SDHC 1.81
- RXST N/A
- Revenue
- SDHC $975,463,000.00
- RXST $139,927,000.00
- Revenue This Year
- SDHC $6.82
- RXST $24.34
- Revenue Next Year
- SDHC $11.61
- RXST $21.83
- P/E Ratio
- SDHC $10.44
- RXST N/A
- Revenue Growth
- SDHC 27.57
- RXST 57.09
- 52 Week Low
- SDHC $17.03
- RXST $13.50
- 52 Week High
- SDHC $39.50
- RXST $66.54
- Technical
- Relative Strength Index (RSI)
- SDHC 45.19
- RXST 25.56
- Support Level
- SDHC $17.87
- RXST $13.79
- Resistance Level
- SDHC $20.33
- RXST $14.93
- Average True Range (ATR)
- SDHC 1.20
- RXST 1.34
- MACD
- SDHC 0.05
- RXST -0.29
- Stochastic Oscillator
- SDHC 56.06
- RXST 9.78
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.